Replies to post #88052 on Biotech Values

[DewDiligence]

PSDV:

So the drug doesn't work and it essentially gives you glaucoma!?!

The device does work to a degree; however, one of the two phase-3 trials clearly failed its primary endpoint and I think the second trial failed also if the p-value threshold is properly adjusted for the use of two doses.

Moreover, I think the company is deliberately delaying its CC until after the market close today in the hope that the bad news will get lost amid the holiday celebration.

If I were able to borrow shares, I would short this one aggressively.

[Democritus_of_Abdera]

Re: Iluvien Investment Opportunity...

So the drug doesn't work and it essentially gives you glaucoma!?!

Where do I sign up for that!

Wallstarb, you’re in luck... According to an amended prospectus filed today, Alimera Sciences is planning to make an initial public offering of stock. see: http://www.sec.gov/Archives/edgar/data/1267602/000095012309072887/g20643a1sv1za.htm

Beware, however, that there will be an immediate dilution due to conversion of outstanding preferred stock into 77,736,832 shares of common stock upon closing of the offering and there will be additional dilutions due to the expected excercise of outstanding warrants and upon the anticipated exercise of stock options by employees or directors accrued under the equity incentive plans....

and, there will be an immediate reduction in working capital by the $15M payment to pSivida which is payable in full upon completion of the public offerring.